Ontario man says medication he's been taking for a decade just quadrupled in price
An Ontario man with Duchenne muscular dystrophy said he was shocked when he got his latest prescription filled for a medication he has been taking for the past ten years.
“I couldn’t believe it. I need to take this medication to help my muscles be able to work a bit better and it has almost quadrupled in price,” said 21-year-old Arun Crishanth of Aurora.
The medication is Deflazacort, a popular drug used to treat Duchenne muscular dystrophy, however it is not covered under government health plans.
The drug is a steroid taken daily to help keep muscles strong and symptoms of muscular dystrophy in check.
Crishanth said he used to get a four month supply of Deflazacort for $187, but when he got his last prescription filled it jumped to $666.
Crishanth was told by his pharmacy Pharmasave that the price increase was due to it being manufactured by a new drug company.
“This new company decided to turn around and quadruple the price. To me it seems ridiculous that they can increase the price that much," said Crishanth.
CTV News Toronto reached out to Pharmasave and a spokesperson said, “Pharmacy pricing in Canada is linked to the cost to purchase the medication from the manufacturer or distributor. The increased pricing experienced by pharmacies (and thus also to patients) is due to manufacturer and distributor changes.”
Deflazacort, a popular drug used to treat Duchenne muscular dystrophy, is photographed.
CTV News Toronto also reached out to Muscular Dystrophy Canada and its CEO Stacey Lintern said in a statement, “Many individuals and their families have been advised by their doctors that Deflazacort is the most suitable option due to its minimal side effects, with some individuals having been on this treatment for 15 years or more. However, the significant increase in price will have detrimental effects on these individuals and their families.”
CTV News Toronto was unable to reach the new manufacturer of Deflazacourt, however Muscular Dystrophy Canada confirmed the price increase was due to a new manufacturer making the drug in Europe which also means increased shipping costs.
While there are cheaper alternatives, they have side effects and many patients with Duchenne muscular dystrophy feel that Deflazacourt is the preferred treatment.
"It’s a drug I’ve been taking for so many years, since I was 10 years old," said Crishanth, who said the drug will now cost him almost $2,000 a year.
"Obviously they should not be able to increase prices like that. It clearly isn't because of inflation, this is just to make some money and I think it's ridiculous that that can happen," said Crishanth.
Muscular Dystrophy Canada said it's important for patients to have equal access to appropriate treatments at a fair cost and that they will continue to try and influence change with regards to the price hike.
If you or your child is experiencing challenges accessing Deflazacort, you can contact Muscular Dystrophy Canada at research@muscle.ca or call 1-800-567-2873 ext. 1114.
CTVNews.ca Top Stories

DEVELOPING Ukrainian President Zelenskyy in Canada, to address Parliament
Ukrainian President Volodymyr Zelenskyy and First Lady of Ukraine Olena Zelenska arrived in Canada Thursday night, and have a full day of events ahead of them, in Ottawa and Toronto.
How to tell if your symptoms are from COVID, a cold or the flu
Telling the difference between a developing case of the flu, a cold or COVID-19 is even more difficult than before, as more distinctive symptoms such as the loss of taste or smell have become less common over time, experts say.
Is a 'no-tipping' policy ready to be adopted by Canadian restaurants?
As Canadians report their frustrations with 'out-of-control' tipping culture, some wonder whether it is time to remove the option to tip at restaurants and is it even possible amid rising food costs?
Movie reviews: 'Dumb Money' is a rousing, high-energy, fist-in-the-air crowd pleaser
This week, pop culture critic Richard Crouse reviews new movies 'Dumb Money,' 'Expend4bles' and 'Stop Making Sense.'
U.S., India talking about Canada murder, no 'special exemption': Biden adviser
The U.S. is in touch with Indians at high levels after Ottawa said Indian government agents had links to the murder of a Sikh separatist leader in Canada, and Washington is giving India no 'special exemption' in the matter, U.S. national security adviser Jake Sullivan said on Thursday.
Ukrainian President Volodymyr Zelenskyy set to arrive in Ottawa for first visit since war
Ukrainian President Volodymyr Zelenskyy is set to arrive in the national capital for his first official visit to Canada since Russia launched a full-scale invasion in February 2022.
B.C. First Nation research finds 158 child deaths at four facilities
An investigation into unmarked graves and missing children by British Columbia's Sto:lo Nation has revealed at least 158 deaths, most of them at an Indigenous hospital.
Canadian-founded Rumble slams 'deeply inappropriate' inquiry from U.K. MPs on Russell Brand content
A Canadian-founded video platform which has found success among right-wing commentators says it will not be removing the ability for Russell Brand to monetize videos on their platform after receiving an inquiry on the subject from the U.K. government amid a wave of sexual assault allegations against the comic.
Law firm awarded $4.5 million contract for David Johnston foreign interference probe
A Toronto-based law firm was awarded a nearly $4.5 million contract to work on former special rapporteur David Johnston's ill-fated foreign interference probe.